dlvr.it
Intraocular Tuberculosis: Current Insights and Emerging Therapeutic Paradigms
.
A Medsky Topics feed composed of posts covering recent news related to Tuberculosis Powered by @medsky.social
Feed on Bluesky
dlvr.it
Intraocular Tuberculosis: Current Insights and Emerging Therapeutic Paradigms
.


www.thelancet.com
The Global Fund and the future of global health
There was a strange sense of relief at the eighth replenishment conference for The Global Fund to Fight AIDS, Tuberculosis and Malaria, which took place on Nov 21, in South Africa. The USA is by far t...

dlvr.it
Drug-induced immune-mediated uveitis: a real-world pharmacovigilance analysis using FAERS and JADER databases
Purpose To analyse drug-associated immune-mediated uveitis (IMU) risk using large-scale pharmacovigilance data. Methods We conducted a retrospective pharmacovigilance study using data from the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) databases, encompassing reports from Q1 2004 to Q4 2024. Disproportionality analysis identified drug-IMU associations using reporting odds ratios (ROR) and information component (IC). Time-to-onset (TTO) was also assessed. Results Disproportionality analysis identified 17 176 IMU cases in FAERS and 2580 in JADER. IMU prevalence was higher in females, with the 30ā80 age group most affected. Antineoplastic and immunomodulating agents, sensory organ drugs and anti-infectives were the most frequently associated drug classes with IMU. Among 117 drugs with positive signals for IMU in FAERS, brolucizumab (ROR025=145.89, IC025=7.08), faricimab (ROR025=134.06, IC025=6.97) and rifabutin (ROR025=82.23, IC025=6.32) exhibited the strongest associations. The three drugs also ranked as the top three drugs with the strongest association with IMU in JADER. The study also highlights significant differences in TTO among various drug classes, with musculoskeletal and sensory organ drugs showing longer TTO compared with other categories. Conclusions Our study highlights the diverse range of drugs implicated in the occurrence or progression of IMU. These findings emphasise the need for early risk assessment, careful monitoring and positive intervention in managing treatments involving high-risk drugs. Future research should focus on elucidating underlying mechanisms and risk factors to develop safer therapeutic strategies.

bit.ly
New vaccines could help us consign tuberculosis to history: hereās how we can do it
New tuberculosis vaccine candidates are currently going through the final stages of clinical trials. We need to work together to ensure they reach the millions who need them quickly and effectively.






bit.ly
How to climate-proof the worldās health systems: Brazil offers a roadmap.
In the Global Health Checkup: Climate guidance from Brazil, trials for a second cholera vaccine, Marburg virus in Ethiopia, UK and the Global Fund, the latest on tuberculosis.

journals.plos.org
Screening and targeted sequencing of stool for microbiologic confirmation and drug resistance determination in paucibacillary tuberculosis
In 2023, an estimated 10.8 million people developed tuberculosis, and 1.25 million people died from this disease, including 161,000 deaths in people with HIV (PWH) in whom tuberculosis remains the lea...

l.euronews.com
Global Fund faces shortfall as European donors cut contributions
The European Unionās influence and contribution to global health is quietly receding in a broader decline in donations to the Global Fund to Fight AIDS, Tuberculosis and Malaria.



www.youtube.com
Opening Session - Union World Conference on Lung Health 2025
YouTube video by International Union Against Tuberculosis and Lung Disease

www.reuters.com


www.theguardian.com
Control of HIV, TB and malaria at risk after global health fund donations fall
Leading past donors including France, Japan and European Commission fail to contribute at pledging summit Control of the deadly infectious diseases HIV, tuberculosis and malaria āhangs in the balanceā after a shortfall in donations to a leading global health fund, advocates have warned. Only $11.3bn of the Global Fund to Fight Aids, TB and Malariaās $18bn (Ā£14bn) targeted budget for 2026 to 2028 has been confirmed so far. Continue reading...

buy.stripe.com
Graze Social Tip Jar
Donate to the Graze Social team and keep the feeds flowing!

reut.rs
World leaders pledge $11 billion to fight AIDS, malaria and TB, short of target
A global health initiative that works to fight AIDS, tuberculosis and malaria raised $11.34 billion at an event in Johannesburg on Friday, below its target for work from 2027-2029.


www.youtube.com
WCLH 2025 - Day 3 Highlights
YouTube video by International Union Against Tuberculosis and Lung Disease